Paediatric idiopathic inflammatory muscle disease: Recognition and management

Drugs

Volumn 65, Issue 10, 2005, Pages 1355-1366

  Pilkington, Clarissa A ^a   Wedderburn, Lucy R ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CD20 ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; TUMOR NECROSIS FACTOR ANTIBODY; VITAMIN D;

AUTOIMMUNE DISEASE; BLOOD EXAMINATION; CHILDHOOD DISEASE; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DERMATOMYOSITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; FUNCTION TEST; HEALTH CARE ORGANIZATION; HUMAN; INCIDENCE; JOINT EXAMINATION; LABORATORY DIAGNOSIS; MEDICAL EXAMINATION; MUSCLE BIOPSY; MUSCLE EXAMINATION; MUSCLE STRENGTH; MYOSITIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL THERAPY; PHYSIOTHERAPY; POLYMYOSITIS; PRACTICE GUIDELINE; PROGNOSIS; QUESTIONNAIRE; RATING SCALE; REVIEW; SIDE EFFECT; SKIN EXAMINATION; TREATMENT OUTCOME;

EID: 22944461430     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200565100-00004     Document Type: Review

References (66)

1. Mendez EP, Lipton R, Ramsey-Goldman R, et al. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003; 49 (3): 300-5
2. Cassidy JT, Petty RE. Juvenile dermatomyositis. In: Cassidy JT, Petty RE, editors. 4th ed. Philadelphia (PA): WB Saunders Company, 2001: 465-504
3. Oddis CV, Conte CG, Steen VD, et al. Incidence of polymyositis- dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County (PA), 1963-1982. J Rheumatol 1990; 17 (10): 1329-34
4. Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol 1995; 34 (8): 732-6
5. Medsger Jr TA, Dawson Jr WN, Masi AT. The epidemiology of polymyositis. Am J Med 1970; 48 (6): 715-23
6. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292 (7): 344-7
7. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292 (8): 403-7
8. Li CK, Varsani H, Holton JL, et al. MHC class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol 2004; 31 (3): 605-9
9. Targoff IN, Miller FW, Medsger Jr TA, et al. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1997; 9 (6): 527-35
10. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362 (9388): 971-82
11. Miller FW, Rider LG, Plotz PH, et al. Diagnostic criteria for polymyositis and dermatomyositis. Lancet 2003; 362 (9397): 1762-3
12. Amato AA, Griggs RC. Unicorns, dragons, polymyositis, and other mythological beasts. Neurology 2003; 61 (3): 288-9
13. van der Meulen MF, Bronner IM, Hoogendijk JE, et al. Polymyositis: an overdiagnosed entity. Neurol 2003; 61 (3): 316-21
14. Miller FW, Rider LG, Plotz PH, et al. Polymyositis: an overdiagnosed entity [letter]. Neurology 2004; 63 (2): 402
15. Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis; 2003 Oct 10-12; Naarden, The Netherlands. Neuromuscul Disord 2004; 14 (5): 337-45
16. Pachman LM, Hayford JR, Chung A, et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol 1998; 25 (6): 1198-204
17. Ramanan AV, Feldman BM. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin N Am 2002; 28 (4): 833-57
18. McCann L, Brown V, Maillard S, et al. Clinical outcomes of juvenile dermatomyositis in the United Kingdom and Ireland: results of 142 children recruited to the national registry and repository [abstract]. Clin Exp Rheumatol 2004; 22 (4): 528
19. Spencer-Green G, Crowe WE, Levinson JE. Nailfold capillary abnormalities and clinical outcome in childhood dermatomyositis. Arthritis Rheum 1982; 25 (8): 954-8
20. Smith RL, Sundberg J, Shamiyah E, et al. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol 2004; 31 (8): 1644-9
21. Ostrov BE, Goldsmith DP, Eichenfield AH, et al. Hypercalcemia during the resolution of calcinosis universalis in juvenile dermatomyositis. J Rheumatol 1991; 18 (11): 1730-4
22. Miyamae T, Mori M, Inamo Y, et al. Multi-center analysis of calcinosis in children with juvenile dermatomyositis [in Japanese]. Ryumachi 2003; 43 (3): 538-43
23. Bode RK, Klein-Gitelman MS, Miller ML, et al. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum 2003; 49 (1): 7-15
24. Ramanan AV, Feldman BM. Clinical outcomes in juvenile dermatomyositis. Curr Opin Rheumatol 2002; 14 (6): 658-62
25. Wadsworth CT, Krishnan R, Sear M, et al. Intrarater reliability of manual muscle testing and hand-held dynametric muscle testing. Phys Ther 1987; 67 (9): 1342-7
26. Lovell DJ, Lindsley CB, Rennebohm RM, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum 1999; 42 (10): 2213-9
27. Huber AM, Feldman BM, Rennebohm RM, et al. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2004; 50 (5): 1595-603
28. Cosnes A, Amaudric F, Gherardi R, et al. Dermatomyositis without muscle weakness: long-term follow-up of 12 patients without systemic corticosteroids. Arch Dermatol 1995; 131 (12): 1381-5
29. Peloro TM, Miller III OF, Hahn TF, et al. Juvenile dermatomyositis: a retrospective review of a 30-year experience. J Am Acad Dermatol 2001; 45 (1): 28-34
30. Rider LG, Miller FW. Idiopathic inflammatory muscle disease: clinical aspects. Baillieres Best Pract Res Clin Rheumatol 2000; 14 (1): 37-54
31. Singh G, Athreya BH, Fries JF, et al. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994; 37 (12): 1761-9
32. Huber AM, Hicks JE, Lachenbruch PA, et al. Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. J Rheumatol 2001; 28 (5): 1106-11
33. Dempster H, Porepa M, Young N, et al. The clinical meaning of functional outcome scores in children with juvenile arthritis. Arthritis Rheum 2001; 44 (8): 1768-74
34. Tse S, Lubelsky S, Gordon M, et al. The arthritis of inflammatory childhood myositis syndromes. J Rheumatol 2001; 28 (1): 192-7
35. Espada G, Weissbord P, Barana M, et al. Dermato-polymyositis (DM: PM): survival analysis and long-term functional outcome in juvenile patients [abstract]. Arthritis Rheum 2002; 46 Suppl. 9: S308
36. Guzman J, Petty RE, Malleson PN. Monitoring disease activity in juvenile dermatomyositis: the role of von Willebrand factor and muscle enzymes. J Rheumatol 1994; 21 (4): 739-43
37. Wedderburn LR, Li CK. Paediatric idiopathic inflammatory muscle disease. Best Pract Res Clin Rheumatol 2004; 18 (3): 345-58
38. Maillard SM, Jones R, Owens C, et al. Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis. Rheumatol 2004; 43 (5): 603-8
39. Brown V, Halkon E, Pilkington C, et al. Revision of the diagnostic criteria for juvenile dermatomyositis. Clin Exp Rheumatol 2004; 22 (4): 528
40. Crowe WE, Bove KE, Levinson JE, et al. Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis. Arthritis Rheum 1982; 25 (2): 126-39
41. Jimenez C, Rowe PC, Keene D. Cardiac and central nervous system vasculitis in a child with dermatomyositis. J Child Neurol 1994; 9 (3): 297-300
42. Kobayashi I, Yamada M, Takahashi Y, et al. Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporin A. Rheumatology 2003; 42 (2): 371-4
43. Elst EF, Kamphuis SS, Prakken BJ, et al. Severe central nervous system involvement in juvenile dermatomyositis. J Rheumatol 2003; 30 (9): 2059-63
44. Pereira RM, Lerner S, Maeda WT, et al. Pericardial tamponade in juvenile dermatomyositis. Clin Cardiol 1992; 15 (4): 301-3
45. Bowyer SL, Blane CE, Sullivan DB, et al. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 1983; 103 (6): 882-8
46. Huber AM, Lang B, LeBlanc CM, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000; 43 (3): 541-9
47. Pachman LM, Cooke N. Juvenile dermatomyositis: a clinical and immunologic study. J Pediatr 1980; 96 (2): 226-34
48. Fisler RE, Liang MG, Fuhlbrigge RC, et al. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002; 47 (4): 505-11
49. Ruperto N, Murray KJ, Gerloni V, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004; 50 (7): 2191-201
50. Heckmatt J, Hasson N, Saunders C, et al. Cyclosporin in juvenile dermatomyositis. Lancet 1989; I (8646): 1063-6
51. Reiff A, Rawlings DJ, Shaham B, et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol 1997; 24 (12): 2436-43
52. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329 (27): 1993-2000
53. Al-Mayouf SM, Laxer RM, Schneider R, et al. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 2000; 27 (10): 2498-503
54. Riley P, Maillard SM, Wedderburn LR, et al. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis: a review of efficacy and safety. Rheumatology (Oxford) 2004; 43 (4): 491-6
55. Hengstman GJ, van den Hoogen FH, Barrera P, et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 2003; 50 (1): 10-5
56. Sprott H, Glatzel M, Michel BA. Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1. Rheumatology (Oxford) 2004; 43 (4): 524-6
57. Maillard S, Wilkinson N, Riley P, et al. The treatment of severe idiopathic myositis with anti-TNF therapy [abstract]. Arthritis Rheum 2002; 44 Suppl. 9: S307
58. Miller ML, Smith R, Abbott KA, et al. Use of etanercept in chronic juvenile dermatomyositis [abstract]. Arthritis Rheum 2002; 44 Suppl. 9: S306
59. Levine TD. A pilot study of rituximab therapy for refractory dermatomyositis [abstract]. Arthritis Rheum 2002; 46 Suppl. 1: S488
60. Looney RJ, Anolik J, Sanz I. B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol 2004; 16 (3): 180-5
61. Maillard S, Jones R, Owens C, et al. Quantitative assessments of the effects of exercise on muscles in juvenile dermatomyositis. Arthritis Care Res. In Press
62. Takken T, Spermon N, Helders PJ, et al. Aerobic exercise capacity in patients with juvenile dermatomyositis. J Rheumatol 2003; 30 (5): 1075-80
63. Isenberg DA, Allen E, Farewell V, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies: development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004; 43 (1): 49-54
64. Pilkington C, Murray KJ, Isenberg D, et al. Development of disease activity and damage indices for myositis: initial testing of 4 tools in juvenile dermatomyositis [abstract]. Arthritis Rheum 2001; 44 Suppl. 9: S294
65. Ruperto N, Ravelli A, Murray KJ, et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford) 2003; 42 (12): 1452-9
66. Rider LG, Miller FW. Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin N Am 1997; 23 (3): 619-55